Prizloncabtagene autoleucel

普龙基奥仑赛

Report date: 2024/04/23 17:57:44

Base Information

Drug NamePrizloncabtagene autoleucel
Drug Alias NameAnti-CD19 anti-CD20 bispecific chimeric antigen receptor T cell therapy (Cellular Biomedicine)Anti-CD20-Anti CD19-BICAR (Cellular Biomedicine)CD19/CD20-directed CAR-T cells (Cellular Biomedicine)Prizlon-cel (AbelZeta Pharma)Autologous second generation CD19/CD20-directed CAR-T cells (Cellular Biomedicine) +[12] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionAnti-CD20Anti-CD19Tumor necrosis factor receptor superfamily member 9 agonists
TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCellular Biomedicine Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCellular Biomedicine Group LtdPeking Union Medical College HospitalPeking University +[5] 
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A